Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2005 5
2006 7
2007 4
2008 6
2009 1
2010 11
2011 4
2012 21
2013 5
2014 9
2015 13
2016 8
2017 5
2018 6
2019 6
2020 9
2022 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 29038319

117 results
Results by year
Filters applied: . Clear all
Page 1
We need a "made in Canada" orphan drug framework.
McMillan HJ, Campbell C. McMillan HJ, et al. CMAJ. 2017 Oct 16;189(41):E1274-E1275. doi: 10.1503/cmaj.170195. CMAJ. 2017. PMID: 29038319 Free PMC article. No abstract available.
Orphan drugs revisited.
McCabe C, Tsuchiya A, Claxton K, Raftery J. McCabe C, et al. QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27. QJM. 2006. PMID: 16504983 No abstract available.
Why we should care about ultra-rare disease.
Harari S. Harari S. Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016. Eur Respir Rev. 2016. PMID: 27246584 Free article. No abstract available.
Rare diseases and effective treatments: are we delivering?
Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G. Luzzatto L, et al. Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5. Lancet. 2015. PMID: 25752159 No abstract available.
The balancing act of orphan drug pricing.
The Lancet. The Lancet. Lancet. 2017 Dec 16;390(10113):2606. doi: 10.1016/S0140-6736(17)33305-6. Lancet. 2017. PMID: 29256396 No abstract available.
117 results